CG Oncology FY2026 Earnings Forecast Raised by HC Wainwright

CG Oncology, Inc. (NASDAQ:CGON) – Equities research analysts at HC Wainwright upped their FY2026 earnings per share estimates for shares of CG Oncology in a research report issued on Friday, November 6th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($2.94) for the year, up from their prior estimate of ($3.60). HC Wainwright has a “Buy” rating and a $100.00 price objective on the stock. The consensus estimate for CG Oncology’s current full-year earnings is ($3.31) per share. HC Wainwright also issued estimates for CG Oncology’s Q4 2026 earnings at ($0.70) EPS, Q1 2027 earnings at ($0.85) EPS, Q3 2027 earnings at ($1.02) EPS, FY2027 earnings at ($3.61) EPS, FY2028 earnings at ($1.33) EPS and FY2030 earnings at $5.00 EPS.

CG Oncology (NASDAQ:CGON) last issued its quarterly earnings results on Friday, November 6th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.19. The company had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $0.55 million. CG Oncology had a negative return on equity of 25.20% and a negative net margin of 3,602.68%.

A number of other equities analysts have also recently issued reports on CGON. Weiss Ratings restated a “sell (d-)” rating on shares of CG Oncology in a report on Thursday, October 15th. Truist Financial increased their target price on shares of CG Oncology from $82.00 to $85.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Royal Bank Of Canada cut their price target on CG Oncology from $81.00 to $79.00 and set an “outperform” rating for the company in a research note on Friday, August 7th. Guggenheim reduced their price objective on shares of CG Oncology from $90.00 to $89.00 and set a “buy” rating for the company in a research note on Monday. Finally, Piper Sandler upped their target price on CG Oncology from $82.00 to $85.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, CG Oncology currently has an average rating of “Moderate Buy” and an average target price of $88.11.

CG Oncology Price Performance

Shares of CGON opened at $74.74 on Tuesday. The stock has a market capitalization of $6.62 billion, a P/E ratio of -27.08 and a beta of 0.35. CG Oncology has a 12-month low of $35.80 and a 12-month high of $80.97. The firm’s 50 day moving average is $68.24 and its 200-day moving average is $66.18.

Insider Transactions at CG Oncology

In other CG Oncology news, Director Leonard E. Post sold 1,000 shares of the business’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $62.06, for a total value of $62,060.00. Following the sale, the director owned 1,000 shares of the company’s stock, valued at $62,060. The trade was a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Over the last 90 days, insiders have sold 3,000 shares of company stock valued at $209,580. Insiders own 4.80% of the company’s stock.

Hedge Funds Weigh In On CG Oncology

Hedge funds have recently modified their holdings of the stock. Fiduciary Financial Advisors acquired a new position in CG Oncology during the second quarter worth $28,000. NFSG Corp acquired a new position in shares of CG Oncology during the first quarter valued at $34,000. Manchester Capital Management LLC lifted its position in CG Oncology by 2,895.5% during the 3rd quarter. Manchester Capital Management LLC now owns 659 shares of the company’s stock valued at $47,000 after purchasing an additional 637 shares during the period. Covestor Ltd lifted its holdings in CG Oncology by 72.6% in the third quarter. Covestor Ltd now owns 770 shares of the company’s stock valued at $55,000 after buying an additional 324 shares during the period. Finally, Fifth Third Bancorp bought a new position in shares of CG Oncology in the 1st quarter worth $74,000. 26.56% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about CG Oncology

Here are the key news stories impacting CG Oncology this week:

• Positive Sentiment: HC Wainwright reiterated its “Buy” rating and $100 price target. It raised its Q4 2026 EPS estimate to a loss of $0.70 from $1.03 and its FY2026 estimate to a loss of $2.94 from $3.60, signaling a less severe expected loss near term. CG Oncology coverage
• Positive Sentiment: Wedbush raised its price target to $84 from $80 and maintained an “Outperform” rating, suggesting continued upside in the analyst’s view. Wedbush ratings
• Negative Sentiment: HC Wainwright cut its EPS forecasts for FY2027 (to a $3.61 loss from $2.83), FY2028 (to a $1.33 loss from $0.65), and FY2030 (to $5.00 profit from $6.88). These lower longer-term expectations temper the positive near-term revisions.
• Negative Sentiment: Guggenheim trimmed its target to $89 from $90, although it kept a “Buy” rating. Guggenheim ratings

About CG Oncology

CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company’s research centers on therapies delivered directly into the bladder.

Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.

CG Oncology has no approved commercial products.